about
Field, genetic, and modeling approaches show strong positive selection acting upon an insecticide resistance mutation in Anopheles gambiae s.s.Probability of emergence of antimalarial resistance in different stages of the parasite life cycle.Prediction of hospital mortality from admission laboratory data and patient age: a simple model.Modelling parasite drug resistance: lessons for management and control strategies.Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy.Measuring windows of selection for anti-malarial drug treatments.Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness.How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance.A Two-Locus Model of the Evolution of Insecticide Resistance to Inform and Optimise Public Health Insecticide Deployment StrategiesTolerance is the key to understanding antimalarial drug resistance.Climate prediction of El Niño malaria epidemics in north-west TanzaniaEntomological indices of malaria transmission in Chikhwawa district, Southern Malawi.Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach.The importance of modelling the spread of insecticide resistance in a heterogeneous environment: the example of adding synergists to bed netsAntimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance.MalHaploFreq: a computer programme for estimating malaria haplotype frequencies from blood samples.The importance of mosquito behavioural adaptations to malaria control in Africa.Incorporating Stage-Specific Drug Action into Pharmacological Modeling of Antimalarial Drug TreatmentQuantifying the pharmacology of antimalarial drug combination therapy.Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies.Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough?Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials.Mathematical models of human african trypanosomiasis epidemiology.ogaraK: a population genetics simulator for malaria.Antibiotic chemotherapy of onchocerciasis: in a bovine model, killing of adult parasites requires a sustained depletion of endosymbiotic bacteria (Wolbachia species).Molecular markers as indicators of antimalarial drug failure rates.Complex dynamics and stability of resistance to antimalarial drugs.Malaria control and the evolution of drug resistance: an intriguing link.Markov chain Monte Carlo and expectation maximization approaches for estimation of haplotype frequencies for multiply infected human blood samples.Reply to "Parasite Strain, Host Immunity, and Circulating Blood Cells with Dead Parasites: Why Predicting Malaria Parasite Clearance Is Not a Simple Task".The Importance of Scientific Debate in the Identification, Containment, and Control of Artemisinin Resistance.Genetics and malaria--more questions than answers.Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'.Coartem (artemether-lumefantrine) in Africa: the beginning of the end?Why we should effectively treat malaria.The genetic polymorphism of Plasmodium vivax genes in endemic regions of Thailand.Insecticide resistance evolution with mixtures and sequences: a model-based explanation.Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria
P50
Q33881129-EF6AF822-56D4-4505-A315-647D6111F33DQ33892979-451BD4CD-DB76-4DD0-A9C2-040149E4E642Q33930900-D0ADC0BF-E6FD-442A-84A3-EB98A80CB403Q34434816-827B29BA-6B3A-4C43-98FD-08922A05B60DQ35065737-9800B4E7-36DC-4F34-8746-41A5F37A31E9Q35744138-742D46B3-AF2B-4CCA-A716-47D779B5A89FQ35906652-DBA422BA-52D7-4126-B1D2-56734E03CB63Q36075783-BCBBCB71-6115-4E43-B056-70FAB4408A1FQ36076111-A73AF336-80AE-4BEB-891E-BCF5CBE7077CQ36153724-35BBB6DA-080B-410A-B0E4-876D9D304616Q36251131-DF4D6CD6-2321-451A-9A7D-D234FFEFFF33Q36365898-4D4A4D2D-BFDE-48D2-A0F1-41CFBB4C81BDQ36431955-AE12AB9F-A3C2-4680-94BE-E153A4213075Q36507422-280DE57E-C918-4428-ADB7-6ABF75552BEEQ36538998-08FFDC33-25B2-47A6-A1E1-15219A55B1EAQ36568195-97C0B795-4A46-4253-B301-5C1ADB2C7C8FQ36717631-52E8EADE-6236-45ED-BF0B-13C5DEA4B6A8Q36798608-C93A3406-BBE3-461E-97FC-58382519CF0EQ36848444-E59A8C06-EC08-4AC0-8B77-364DCA9CDA3EQ36888028-90B22AE5-2149-4DBE-8A95-CC0BF3EACC9FQ37283299-FB571097-2ABA-482B-BDC7-CEE5EF74BF0FQ37503352-EB3EC5E1-33DD-41F8-B606-2564E2263724Q37685088-9AF8DBDD-F6CC-49C3-BA52-BFE0F73D120CQ38225084-05D1022B-70CA-4378-BA24-AC976BA85424Q38375724-42130803-F4CA-4862-91E5-681E8D8C35E2Q38876697-AFC4E78F-028C-4F2A-80E2-FBD5FE6E9857Q39023496-24FEDB3E-1850-46FB-8318-2A7718FFB254Q39055303-2B7409EF-BB65-4728-B04B-E4B8CE378958Q39055325-63C65D2C-43EA-40EE-AA7E-CCC8D6043637Q39055396-7FEE4664-15E9-4497-861E-06E1CABF0CE1Q39127968-961E94F2-D8ED-4822-9AF1-8D535C3B7350Q42564004-0CF26BF3-C0E0-4CF8-905B-1E20AC5578BFQ43595043-0BEF8D28-B59A-46A5-89BC-8D48F453BC04Q45147472-D7048E95-6268-4CF7-BBB6-D9151AADA297Q45232650-F15EB05A-6AA0-4582-B4AB-6CBF039A86A2Q46681966-9AD70A3A-3792-482D-AC8D-E9906662B5CFQ47971035-8BBD8F8E-E438-4F56-9F40-531894BD528AQ47995977-030A29FC-44DF-40A3-91E9-953A99B03D1DQ49963058-AE7CE9D2-16E7-428E-8C49-34216139CB0AQ56770456-AFB10D0D-1BAE-4F1A-892F-E16341E69ABA
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ian M Hastings
@ast
Ian M Hastings
@en
Ian M Hastings
@es
Ian M Hastings
@nl
Ian M Hastings
@sl
type
label
Ian M Hastings
@ast
Ian M Hastings
@en
Ian M Hastings
@es
Ian M Hastings
@nl
Ian M Hastings
@sl
prefLabel
Ian M Hastings
@ast
Ian M Hastings
@en
Ian M Hastings
@es
Ian M Hastings
@nl
Ian M Hastings
@sl
P106
P21
P31
P496
0000-0002-1332-742X